Table 11 Costs avoided by age group
Influenza-associated costs | Age group | ||||
|---|---|---|---|---|---|
0–4 years | 5–11 years | 12–49 years | 50–59 years | ≥60 years | |
Direct costs | |||||
Laboratory diagnosis | 1,705,270 | 5,970,134 | 2,729,797 | 1,060,393 | 1,805,053 |
Medical consultations | 1,537,700 | 7,238,955 | 3,285,458 | 1,040,038 | 1,476,373 |
Drugs | 200,447 | 1,403,033 | 638,823 | 177,367 | 170,223 |
Hospitalisations | 12,948,383 | 40,807,242 | 18,282,368 | 7,697,330 | 13,775,872 |
Influenza immunisation to school-aged population | −27,421,602 | ||||
Total direct costs avoided (third-party payer perspective) | 16,391,799 | 27,997,763 | 24,936,446 | 9,975,128 | 17,227,521 |
Indirect costs | |||||
Productivity loss | 2,243,927 | 7,026,866 | 3,186,588 | 1,357,530 | 616,517 |
Premature death | 16,215 | 137,958 | 526,445 | 229,548 | 119,216 |
Total indirect costs avoided | 2,260,142 | 7,164,824 | 3,713,033 | 1,587,079 | 735,733 |
Total costs of influenza avoided (societal perspective) | 18,651,941 | 35,162,586 | 28,649,479 | 11,562,206 | 17,963,254 |